Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Nxera Pharma’s story from late 2025 to mid‑2026 is one of restructuring, pipeline maturation, and clever non‑dilutive financing. Progressing from oldest to newest releases:

• October 2025: The company presented Phase 1 safety and early efficacy data for its oral EP4 antagonist HTL0039732 at ESMO, with confirmed partial responses in hard‑to‑treat cancers. Simultaneously, Q3 2025 results showed a widening operating loss (JPY 5.9 bn) but the launch of a proprietary obesity/metabolic pipeline (GLP‑1 agonist plus six GPCR programs) and a $10 m AbbVie milestone.
• November 2025: A restructuring was announced, targeting JPY 50 bn sales and ~30% operating margin by 2030; R&D spend in the UK to be cut by ~JPY 3.5 bn, 15% workforce reduction, and executive bonuses slashed.
• December 2025: Boehringer Ingelheim declined to license the GPR52 agonist program, returning full rights to Nxera. NX‑0149, Phase 2‑ready, will be out‑licensed in 2026.
• January 2026: Nxera licensed vamorolone (AGAMREE®) for Duchenne muscular dystrophy from Santhera for Japan, Korea, Australia and New Zealand – $40 m upfront ($30 m cash + $10 m equity) and up to $165 m milestones. Also, a $3.6 m Centessa milestone for ORX142 was received. Positive Phase 3 daridorexant data in South Korea was reported, with marketing application planned in Q1.
• February 2026: FY2025 results: revenue JPY 29.6 bn, operating loss JPY 8.46 bn, net loss JPY 12.5 bn. Cash at year‑end JPY 20.4 bn. A $1.8 m milestone from Centessa for ORX489. A separate early‑stage GPCR program was out‑licensed to a new VC‑backed company (NewCo), with Nxera receiving equity and retaining Japan/APAC rights.
• March 2026: Daridorexant marketing application submitted in South Korea.
• April 2026: A wave of positive but routine events: Centessa to be acquired by Eli Lilly for up to $7.8 bn (Nxera keeps royalties/equity); a $22.5 m Neurocrine milestone for Phase 2 start of NBI‑1117570 in schizophrenia; AbbVie $10 m milestone; Taiwan approval for QUVIVIQ; second Lilly collaboration milestone (undisclosed amount).
• May 2026 (1 May): Q1 2026 results delivered a turnaround – net profit JPY 1.79 bn, revenue JPY 11.26 bn, driven by seven R&D milestones. The release disclosed multiple partner advances and highlighted the Centessa/Lilly deal.
• 8 May 2026: Nxera filed a patent infringement lawsuit against OMass Therapeutics over its miniG platform technology – a defensive move to protect core IP.
• 11 May 2026 (latest): Nxera announced the progression of the previously flagged NewCo spin‑out. The company entered an investment agreement, granted an exclusive worldwide license (ex‑Japan and certain APAC) for a pre‑clinical GPCR program, and obtained a “significant minority equity stake.” Nxera may receive up to $275 m in milestones plus royalties, and retains Japan/APAC rights. Dr. Patrik Foerch joins NewCo’s board.

The 11 May release is essentially the formal closing/update of the transaction previewed in the Q1 report and the earlier February NewCo announcement.

The most recent news (11 May 2026) is a routine positive – it fills in details of a deal whose existence was already communicated. No new material information is added beyond the milestone ceiling ($275 m), the equity stake, and governance. This is Nxera’s second asset spin‑out (following Orexia/Centessa), demonstrating a repeatable model to advance non‑core assets without straining the balance sheet. While the milestone potential is meaningful (roughly 3–4× the current cash position), it is back‑end loaded and contingent on clinical success. Markets had already priced in the concept of such a deal; the additional specifics are incrementally positive but not game‑changing. There is no first‑time strategic investor of the calibre that would warrant a “game changer” label. The news does not alter the fundamental earnings or cash‑flow trajectory in the near term.

Nxera Pharma is a Japanese biopharmaceutical company built around its proprietary NxWave™ GPCR structure‑based drug discovery platform. The company has two commercial products in Japan: PIVLAZ® (clazosentan) for cerebral vasospasm and QUVIVIQ® (daridorexant) for insomnia. It recently in‑licensed vamorolone (AGAMREE®) for Duchenne muscular dystrophy in Asia‑Pacific. Its pipeline is rich in partnered programs: muscarinic agonists with Neurocrine (Phase 2/3), orexin agonists with Centessa (now being acquired by Lilly), multi‑target collaborations with Lilly and AbbVie, and an EP4 antagonist in Phase 2a with Cancer Research UK. The flagship remains the NxWave platform, which generates novel GPCR‑targeted small molecules and underpins the licensing-driven business model.